Related Experiment Video
Updated: Jul 18, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
[Anticoagulants and cancer: beyond thromboembolic disease prevention]
1Service de médecine interne générale, Département de médecine interne, HUG, 1211 Genève 14. Francois.Jornayvaz@hcuge.ch
Abstract:
The association between cancer and thromboembolic disease is well documented. The procoagulant capacity of tumor cells seems to be related to malignant transformation. In this context, a preventive effect on tumoral progression by the adjunction of an anticoagulant such as vitamin K antagonists, unfractionated heparin or low molecular weight heparin (LMWH) was studied. Some studies concluded to a modest increase in survival in patients treated by LMWH in adjunction to conventional chemotherapy and/or radiotherapy. This benefit seems to be related to an inhibitory effect on tumoral progression. LMWH seems promising in an eventual routine clinical use. However, their type, dose and duration and in which cancers has to be further defined.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cancer Prevention
Some...
Cancer Prevention
Some...